Dapsone for refractory chronic idiopathic thrombocytopenic purpura

    loading  Checking for direct PDF access through Ovid

Abstract

Summary

Fifteen patients with refractory chronic idiopathic thrombocytopenic purpura (ITP) were treated with dapsone (100 mg/d) for 1-31 months. The overall response rate to dapsone was 40 percent. Five patients responded in 1 month and one patient in 2 months. No pretreatment characteristics - sex, age, platelet count or duration of ITP - were correlated with response to dapsone.

Treatment was well tolerated.The most frequent adverse effect was dose-related haemolytic anaemia. In our experience, dapsone provides an inexpensive and well-tolerated alternative for patients with ITP who had inadequate responses to conventional therapy.

Related Topics

    loading  Loading Related Articles